Company Profile - JSP PHARMACEUTICAL MANUFACTURING (THAILAND) PUBLIC COMPANY LIMITED สำนักงานคณะกรรมการกำกับหลักทรัพย์และตลาดหลักทรัพย์ Printed on 09 August 2024 20:12 Company Profile JSP
Earlier, the SEC filed a criminal complaint against the 10 entities with the Department of Special Investigation (DSI) on account of fabricating financial statements, disclosing false information in
complaint against 10 individuals with the Department of Special Investigation (DSI) on account of fabricating STARK financial statements, disclosing false information in the registration statement for
disclosure of information that is insufficient and incomplete for investment decision making, or misleading to investors in a manner of concealing, disguising or fabricating information in the particulars, or
1 No. ECF2 029/2561 28 June 2018 Subject The Entering into an Investment of the construction of the Manufacturing Plant and Distributing of the Medium Density Fiber Board or MDF Board in Narathiwat
dialysate and medical supply manufacturing and distribution, which increased from the same period of the previous year for 5.31 million baht or 22.37%, resulting in the increase of the Company Group’s gross
medical supply manufacturing and distribution, which increased from the same period of the previous year for 4.80 million baht or 18.99%, resulting in the increase of the Company Group’s gross profit for
vs. total revenue has increased significantly. The main factors behind this unwelcome trend was a jump in fuel (petroleum coke) prices, and increased manufacturing cost of machinery equipment. However
. Prachnon Termritikulchai who is a Director and CEO of UBIS (Asia) Public Company Limited. 3 Information : Purchase of 6 machineries (Second hand) for manufacturing Size of transaction : It is considered as